Xijing Hospital of

Company snapshot

Xijing Hospital of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Primary Biliary Cirrhosis, Gastric Intestinal Metaplasia. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1), approved (1).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Xijing Hospital of. Not investment advice.

• What is Xijing Hospital of?

  Xijing Hospital of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Primary Biliary Cirrhosis, Gastric Intestinal Metaplasia. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA,

• Is Xijing Hospital of publicly traded?

  Xijing Hospital of appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Xijing Hospital of develop or market?

  We link 2 drug profile(s) where Xijing Hospital of is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/xijing-hospital-of-digestive-diseases#company-drugs.

• What are the latest developments for Xijing Hospital of?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Xijing Hospital of focus on?

  Xijing Hospital of focuses on Primary Biliary Cirrhosis, Gastric Intestinal Metaplasia based on our analysis of their pipeline programs and drug development activities.